Clinical Guides
Measles
A clinically focused guide to recognising suspected measles, protecting others before confirmation, managing complications and vitamin A safely, and acting within India’s immunisation and surveillance systems, with immediate airborne precautions, prompt notification and safe transfer planning as clinical priorities.
MedNext Academy | 12 min read
Measles
A clinically focused guide to recognising suspected measles, protecting others before confirmation, managing complications and vitamin A safely, and acting within India’s immunisation and surveillance systems, with immediate airborne precautions, prompt notification and safe transfer planning as clinical priorities.
Summary
Measles is an acute, highly contagious airborne viral illness. The classic sequence is fever and malaise, cough, coryza and conjunctivitis, sometimes with Koplik spots, followed by a descending maculopapular rash. It can cause pneumonia, diarrhoea with dehydration, otitis media, encephalitis, blindness and death; risk is greatest in young children, pregnant people, adults, people with immune compromise and those with malnutrition or vitamin A deficiency. Immunity after two appropriate measles-containing vaccine doses is the principal preventive measure.
Clinically compatible illness is a public-health emergency, not a diagnosis to await after a routine appointment. Mask and separate the patient immediately, avoid unnecessary time in shared waiting areas, notify the relevant local public-health pathway, collect specimens as directed, and begin exposure assessment while confirmation is pending. The clinical appearance overlaps with rubella, dengue, parvovirus, drug eruptions and many other febrile rashes; laboratory testing and epidemiological linkage matter, particularly for sporadic cases and outbreaks. There is no routine curative antiviral therapy. Care is supportive and complication-directed, with vitamin A used under clinician supervision for indicated children.
In healthcare, use airborne precautions for a suspected or confirmed case. Infected people are isolated through four days after rash onset, and infectiousness begins four days before rash onset. Absence of a known exposure must not delay isolation. If transfer is needed, alert the receiving team first and minimise passage through shared space. This protects infants, pregnant people and people with immune compromise while laboratory and public-health work proceeds. [CDC Clinical Overview of Measles, Key points; Clinical features; Isolation]
How Common Is It?
Measles burden changes rapidly with immunity gaps, travel, outbreaks and disruption to routine services. A single current prevalence number is less useful at the bedside than knowing whether there is local transmission, an exposure cluster or a recent travel link. WHO describes measles as a continuing global threat despite an effective vaccine, with severe outcomes concentrated in under-immunised groups and settings where nutrition and health systems are strained. Clinical suspicion must therefore be driven by syndrome and exposure, not by an assumption that vaccination programmes have made measles impossible.
In India, measles and rubella are priority vaccine-preventable diseases under national surveillance. The 2024–25 Ministry of Health and Family Welfare annual report lists measles-rubella dose one at 9–12 months and dose two at 16–24 months in the National Immunization Schedule, while special campaign or outbreak advice may differ by place and time. The schedule is not proof of a child’s individual vaccination status; obtain the record where possible. Do not fabricate district coverage or current outbreak numbers from national documents. [WHO Measles fact sheet, prevention section; MoHFW Annual Report 2024–25, National Immunization Schedule table]
Risk Factors
Susceptibility is greatest in people without evidence of immunity, including infants too young for routine vaccination, children who missed doses, people displaced from routine services, and unimmunised close contacts. Exposure in crowded homes, schools, healthcare facilities, transport settings or shelters increases transmission opportunity because virus can remain infectious in air after an infected person leaves. International travel and contact with a febrile-rash illness should be asked about, but absence of travel does not exclude locally acquired infection.
Severe disease is more likely in children under five, adults, pregnancy, immune suppression, HIV and malnutrition, especially vitamin A deficiency. A partially immune or immunoglobulin-treated person can have modified illness with less typical features, so a mild rash does not justify abandoning isolation where exposure risk is credible. Record chemotherapy, transplant, biologics, high-dose corticosteroids, HIV status where appropriate, pregnancy, nutrition, current medicines and vaccine history. Vaccine history helps risk assessment but does not replace notification, testing and infection control for a clinically compatible case. [WHO Measles fact sheet, complications section; CDC Clinical Questions, modified measles and high-risk groups]
Diagnosis
History
Ask the date and order of fever, cough, coryza, conjunctivitis, oral lesions and rash. A classic rash begins on the face/upper neck and spreads down, but documentation of timing and morphology is more useful than a memorised picture. Ask about exposure to a febrile-rash case, travel, school or household clusters, vaccination records, immune compromise and pregnancy. Assess intake, urine output, breathing, ear pain, confusion, seizure, severe diarrhoea and visual symptoms; these identify complications, not merely diagnostic detail. Record all locations from the four days before rash onset onward, healthcare visits and close contacts; public-health teams need this exposure timeline, not a retrospective guess after laboratory confirmation.
Examination
Use airborne precautions before a full examination. Record fever, respiratory distress, hydration, oxygenation, mental state and nutrition. Look for conjunctivitis, Koplik spots and a generalised non-vesicular maculopapular rash, while examining for pneumonia, otitis, dehydration, encephalopathy and secondary bacterial infection. In an unstable child, resuscitation and senior review precede a prolonged search for oral signs.
Investigations
For a suspected case, obtain serum for measles IgM and a throat or nasopharyngeal swab for RT-PCR at first contact according to the public-health laboratory pathway; do not wait for an ideal specimen window if follow-up is uncertain. RT-PCR can confirm infection, while IgM must be interpreted with timing, vaccination and epidemiology in mind. Test or image complications selectively: pulse oximetry, chest imaging, blood culture or lumbar puncture answer clinical questions, not the measles diagnosis itself. [CDC Clinical Overview, diagnosis/laboratory testing; WHO Surveillance Standards, specimen collection and case definitions]
Differential Diagnosis
The broad differential of fever and a maculopapular rash includes rubella, dengue, parvovirus B19, roseola, enterovirus, scarlet fever, meningococcal disease, rickettsial infection, acute HIV, secondary syphilis and drug eruption. The probability depends on age, geography, season, exposure, immunisation, illness severity, rash chronology, mucosal findings and basic examination. In India, dengue or other local infections may be more common in some settings, but that does not make it safe to send a potentially infectious measles case into an unprotected waiting room.
Rubella may resemble measles but has distinct public-health implications, especially around pregnancy. Varicella is vesicular rather than a uniform maculopapular eruption. Toxic shock, meningococcaemia and severe drug reactions can deteriorate quickly and require emergency treatment, not a delayed virology result. Kawasaki disease or MIS-C may enter paediatric differentials according to fever duration and multisystem findings. Vaccine-associated rash, recent vaccination and false-positive serology can complicate interpretation; discuss equivocal results with the designated laboratory or public-health team rather than declaring cure or an outbreak on one result. [WHO Surveillance Standards, case classification and interpretation cautions; CDC Clinical Overview, testing section]
Management
Supportive care is active care: maintain hydration and nutrition, manage fever and discomfort safely, monitor respiratory status, and reassess for pneumonia, otitis media, severe diarrhoea, dehydration, croup, encephalitis and bacterial superinfection. Admit or escalate early for hypoxaemia, respiratory distress, altered consciousness, persistent seizures, inability to drink, shock, severe malnutrition, pregnancy, significant immune compromise or unreliable home observation. Antibiotics are not routine measles treatment; prescribe them only for a suspected or confirmed bacterial complication using current local guidance. Before discharge, ensure the caregiver can recognise increasing work of breathing, poor intake, reduced urine, lethargy and seizure, knows how to isolate at home, and has a feasible route back to care.
Vitamin A reduces morbidity and mortality in affected children in settings with vitamin A deficiency and is recommended by WHO for suspected measles in children under five, immediately on diagnosis and again the next day. It is a high-dose medicine, not a wellness supplement or substitute for vaccination. Dose, formulation, age, nutrition, hepatic risk and pregnancy require clinician oversight; excess can be toxic. A third dose may be indicated in eye disease/vitamin A deficiency under specialist guidance. Immunoglobulin or post-exposure vaccination decisions belong to time-sensitive public-health and paediatric pathways, because eligibility and intervals depend on age, immunity, pregnancy and immune status. [WHO Measles fact sheet, treatment and vitamin A section; CDC Measles Treatment Overview, vitamin A and complications]
Prescribing Information
There is no routinely approved specific antiviral treatment for uncomplicated measles. Give fluids, nutrition support and antipyretics appropriate to age and comorbidity; avoid using antibiotics merely because the illness is viral, but investigate and treat bacterial pneumonia, otitis, sepsis or another complication when evidence supports it. Avoid aspirin in children because of Reye syndrome risk. Cough mixtures, antibiotics and corticosteroids should not be reflex prescriptions for a rash illness; each has a separate indication and possible harm.
Vitamin A must be prescribed as an age-specific, short supervised course when indicated, not continued indefinitely. CDC’s clinician summary gives 50,000 IU for infants under 6 months, 100,000 IU for 6–11 months and 200,000 IU from 12 months, administered on diagnosis and repeated next day; WHO recommends two doses for suspected cases under five. Local paediatric protocols may specify product and handling. Do not use high-dose vitamin A in pregnancy without specialist advice because teratogenicity is a concern. Check all medicines for dehydration-related renal risk, swallowing ability and duplicate over-the-counter ingredients. [CDC Measles Treatment Overview, Vitamin A dosing and toxicity cautions; WHO Measles fact sheet, vitamin A recommendation]
When to Refer
Emergency referral or admission is required for respiratory distress, hypoxaemia, cyanosis, dehydration with poor intake or shock, altered mental state, seizure, focal neurological sign, severe headache with encephalopathy, severe diarrhoea, visual symptoms, bleeding, suspected sepsis or concern for airway obstruction. Infants, pregnant people, immunocompromised people and severely malnourished patients warrant a lower threshold for paediatric, obstetric, infectious-disease or critical-care input. The referral should state that measles is suspected before arrival so isolation can be arranged.
Every suspected case also needs immediate public-health notification through the applicable facility, district or state mechanism. Notify before confirmation where required; delay costs time for contact tracing, infection-control advice and outbreak investigation. Refer to ophthalmology for keratitis or visual symptoms, audiology/ENT for persistent hearing concern, neurology for encephalitis or post-infectious neurological disease, and nutrition services for malnutrition. A clinically well person with an uncomplicated course may still need remote follow-up and clear return precautions; no improvement in fever or breathing should not be managed as ‘just the rash’. [CDC Clinical Overview, reporting and isolation sections; NCDC IDSP VPD surveillance page]
Red Flags
Red flags during a suspected or confirmed measles illness are fast breathing, chest indrawing, hypoxaemia, persistent fever with clinical decline, lethargy, confusion, seizure, severe headache, stiff neck, inability to drink, reduced urine, repeated vomiting, severe diarrhoea, haemodynamic instability, purpura, eye pain, reduced vision or a rapidly progressive rash. These may indicate pneumonia, encephalitis, dehydration, sepsis, corneal disease or a different life-threatening diagnosis. A very young infant, pregnancy, immune suppression and severe malnutrition lower the threshold for assessment even when symptoms initially look mild.
Public-health red flags are a compatible rash illness after exposure, multiple linked cases, illness in a healthcare worker, or a patient who spent time in a shared waiting area before isolation. Alert infection prevention immediately; the aim is to identify exposed people and protect those at high risk, not to assign blame. A patient who is immunocompromised may shed virus longer than the standard rash-based isolation interval, so the isolation duration needs specialist/public-health advice. New otalgia, cough worsening after initial improvement, focal chest signs or recurrent fever should trigger assessment for bacterial complication. [CDC Clinical Questions, isolation in immunocompromise; CDC Clinical Overview, complications and infection-control sections]
Indian Clinical Context
India’s National Immunization Schedule lists MR-1 at 9–12 months and MR-2 at 16–24 months; outbreak action, catch-up decisions and post-exposure pathways must follow current state/district public-health direction rather than an article’s fixed schedule. The MoHFW annual report describes linkage between vaccine-preventable-disease surveillance and IDSP, including weekly sharing of cases and laboratory reports and joint outbreak investigations. NCDC identifies measles and rubella among the priority diseases being transitioned into national VPD surveillance operations.
At facility level, isolate first and contact the local surveillance/infection-control pathway for specimen routing, notification and contact advice. Access may be limited by distance, negative-pressure rooms, laboratory transport, vaccine-record gaps and bed availability; these are reasons to communicate early, not reasons to omit notification. In a child with poor diet, wasted growth or eye signs, integrate nutrition and paediatric care. Do not claim a uniform legal notification form, local outbreak threshold or immunoglobulin availability across India without checking the current district/state instruction. [MoHFW Annual Report 2024–25, VPD surveillance and schedule pages; NCDC IDSP VPD surveillance page]
NMC Competency Mapping
Measles maps to NMC learning across paediatrics, community medicine, microbiology, pharmacology, ophthalmology, ENT, emergency care, nutrition and AETCOM. At Know level, learners should describe airborne transmission, prodrome, Koplik spots, rash progression, complications, high-risk groups, two-dose measles-containing vaccination and why clinical suspicion triggers public-health action. At Know How level, they should differentiate a febrile maculopapular rash, select paired serum and respiratory specimens with laboratory/public-health support, identify pneumonia, dehydration and encephalitis, and explain the indication and risks of vitamin A.
At Show How level, learners should recognise a suspected case in triage, arrange masking and airborne separation, take an exposure/vaccination history without stigma, document notification, and counsel caregivers on hydration and danger signs. They should not independently determine outbreak response, post-exposure prophylaxis, high-dose vitamin A in pregnancy, or the interpretation of discordant measles laboratory results. AETCOM includes protecting other patients before definitive confirmation, communicating isolation without blame, and respecting disability, nutrition and access barriers. [NMC CBME Curriculum 2024, paediatrics, community medicine, microbiology, pharmacology, ophthalmology, ENT and AETCOM domains]
Key Exam Pearls for NEET PG
Measles classically produces fever, cough, coryza, conjunctivitis and Koplik spots before a descending maculopapular rash. Transmission is airborne; patients are infectious before rash onset and isolation generally continues through four days after rash onset, with longer precautions for immune compromise. A suspected case is enough to trigger immediate masking, separation, notification and specimen planning.
Confirm using measles IgM and RT-PCR on a respiratory specimen according to timing and public-health direction; do not delay collection awaiting the perfect time. Major complications are pneumonia, diarrhoea/dehydration, otitis media, encephalitis and blindness, especially with young age, malnutrition/vitamin A deficiency and immune suppression. There is no routine antiviral treatment. Antibiotics treat bacterial complications, not measles itself.
Vitamin A is used under clinician supervision for children with suspected measles; it is not vaccine replacement and can be toxic in excess. In India, MR-1 is listed at 9–12 months and MR-2 at 16–24 months in the national schedule. Rubella, dengue, drug eruptions and other febrile rashes remain differentials, but infection control must precede diagnostic certainty. [CDC Clinical Overview, key points and testing; MoHFW Annual Report 2024–25, National Immunization Schedule]
Frequently Asked Questions
Should a suspected measles patient wait for laboratory confirmation before isolation?
No. A compatible febrile-rash illness should be masked and separated immediately, with airborne precautions in healthcare settings and prompt public-health contact. Laboratory confirmation is essential for sporadic cases and outbreaks, but it comes after the immediate action that prevents avoidable exposures. If possible, plan the patient’s arrival so they bypass a crowded waiting area. The exact local pathway for notification, specimen transport and contact management should be confirmed with the facility infection-control or public-health team.
Does vitamin A cure measles or replace measles-rubella vaccination?
No. Vitamin A is supportive treatment for indicated children and may reduce severe outcomes where vitamin A deficiency is common. It does not kill measles virus, does not provide future immunity and does not replace two-dose measles-containing vaccination. It must be given in an age-appropriate short course under clinician supervision because excess vitamin A can be toxic, and high doses are unsafe in pregnancy without specialist advice. Hydration, nutrition and early detection of pneumonia or encephalitis remain essential.
Why are blood and throat or nasopharyngeal specimens both collected?
Serum measles-specific IgM can provide evidence of recent infection, while RT-PCR on a respiratory specimen can confirm measles RNA and contribute to public-health investigation. Test performance and interpretation depend on timing, vaccination history, epidemiological linkage and local laboratory protocols. Collecting at first contact reduces loss to follow-up and allows public-health action to proceed on credible evidence. A positive or equivocal result should be interpreted with the designated laboratory and surveillance team, not in isolation from the clinical picture. The specimen request should identify rash-onset date, vaccination history and exposure history, because these details guide laboratory interpretation and outbreak classification.
Can a fully vaccinated child still be assessed for measles?
Yes. Two documented doses make measles much less likely, but no history alone should override a compatible syndrome with exposure risk, particularly during an outbreak or in an immunocompromised person. Modified illness can be less typical in people with pre-existing immunity. The safe approach is to isolate and notify while clinicians and public-health teams assess vaccine documentation, exposure, alternatives and laboratory testing. Vaccination status should guide probability and contact management, not justify exposing other patients before review.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic